Folie 1

BORDERNETwork Training on P ost- E xposure- P rophylaxis Dr. med. Wolfgang Gthoff / Alexander Leffers, M.A. www.bordernet.eu www.aidshilfe-potsdam.de

Folie 2

This presentation arises from the BORDERNETwork project which has received funding from the European Union, in the framework of the Health Program, and co- funding of the Ministry of Environment, Health and Consumer Protection of the Federal State of Brandenburg. The sole responsibility of any use that may be made of the information lies with the authors (SPI, AIDS-Hilfe Potsdam e.V.)

Folie 3

Table of Contents Transmission Conditions for PEP Guidelines on PEP Blood Control Problems with PEP

Folie 4

PEP HIV - Exposure When? Injury with HIV contaminated instruments Wetting of open wounds and mucosa with HIV contaminated fluids Unprotected sex with an HIV infected person Use of HIV contaminated needles (needle sharing) Transfusion of HIV contaminated blood or blood products Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der sterreichischen AIDS- Gesellschaft (AG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

Folie 5

PEP - Guidelines The ultimate goal of PEP is: to suppress any viral replication that may occur, to shift the biological advantage to the host cellular immune system to prevent or abort early infection http://www.who.int/hiv/pub/guidelines/PEP/en/ http://www.hivguidelines.org/wp- content/uploads/2009/05/pep_card.pdf http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5011a1.ht m

Folie 6

Occupational PEP Probability of Transmission Factors influencing transmission: Kind of transmitting material (Viral concentration is highest in the blood) Kind of exposure: Hollow needle Cut injury Open wound Exposure of mucosa Viral concentration from index person Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der sterreichischen AIDS- Gesellschaft (AG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

Folie 7

Average risk: Percutaneous 0.3% Mucous membrane 0.1% Non-intact skin

PEP when to start and time limits Entry and Fusion2h DNA-Integration in nucleus12h Viral replication after another12h PEP within 24h (best - start within first 2h) >72h after Exposition: PEP is not practical Replication of HIV and Targets of Therapy Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der sterreichischen AIDS- Gesellschaft (AG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

Folie 16

Medications for PEP (German Austrian Guidelines) Tenofovir 300mg plus Emtricitabin 200mg as combination product (Truvada 1x1 pill) combined with Kaletra (Lopinavir + Ritonavir) 2 x 400/100mg or Sustiva 1 x 600mg Alternative: Combivir 2 x 1 pill (Zidovudin + Lamivudin) Alternative: Invirase (2 x 1000mg plus Ritonavir 2 x 100mg) or Fosamprenavir Indinavir Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der sterreichischen AIDS- Gesellschaft (AG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

Folie 17

European Guidelines HIV- rapid test from Index person If Index persons HIV-RNA > 1000 copies/ml testing of drug resistance Start PEP if possible within 4h and not later then 48h Duration: 4 weeks Medication: Truvada (TDF/FTC) 1 x 1 pill Alternative: Combivir (ZDV/3TC)2 x 1 pill + Kaletra (LPVr) 2 x 2 pills Alternative: Invirase 500(SQV) 2 x2 capsules and Norvir (RTV) 2 x 100mg Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der sterreichischen AIDS- Gesellschaft (AG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

Folie 18

Blood Controls Serologic control (HIV, possible HBV, HCV): at the start after 6 weeks, after 3 month after 6 month Laboratory tests: at the start, after 2 weeks and after 4 weeks: Blood count, liver enzymes, kidney function, blood sugar, urine

Folie 19

Problems regarding HIV PEP Pregnancy and lactation period No substance is harmless! PEP only at high risk Experience only with Retrovir and Epivir Sustiva (Efavirenz) is contraindicated!

Folie 20

Period between exposition and starting PEP not longer than 24 h Problems regarding HIV PEP

Folie 21

High risk through massive inoculation of infections material

Folie 22

Problems regarding HIV PEP Strong side effects of HAART (mental Efavirenz)

Folie 23

Problems regarding HIV PEP Index person gets HAART and drug resistance is probable Course of CD4 cells Opportunistic infections (OI)

Folie 24

HIV-Infection known? How fast is an HIV-test possible? HIV- rapid tests every time for every physician available? PEP - Index person

Folie 25

Treatment Algorithm Did an exposure to a potentially HIV-infected fluid occur? Did a significant risk of transmission of HIV occur? (Contact of a HIV negative person with an HIV positive person (index person/source patient) Is the patient presenting within ideally 2 hours, not later than 72 hours of the exposure? Can the source patient be interviewed? Initiation of PEP regimen: PEP within 24h (best - start within first 2h) HIV monitoring YES NO No indication of PEP No follow-up needed No indication of PEP No follow-up needed PEP not indicated Follow-up HIV testing Adopted from: New York State Department of Health/ AIDS Institute: Recommendations for HIV Postexposure Prophylaxis (PEP) URL: http://www.hivguidelines.org/wp-content/uploads/2009/05/pep_card.pdf Adopted from: Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V.) und der sterreichischen AIDS-Gesellschaft (AG) et al. in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33. If yes: interview on HIV status or infection risk, resp. test/rapid test on HIV If no: belongs the source patient to a high risk group (with high prevalence) If yes: Individual benefit-risk assessment If no: PEP not indicated Serological test of source patient is confirmed HIV negative no evidence of acute retroviral syndrome Serological test of source patient is confirmed HIV positive Evidence of acute retroviral syndrome occurs Source patient is unknown, unwilling etc. Stop PEPContinue PEP for 4 weeks

Folie 26